Belite Bio BLTE Insider Ownership

Updated Oct 6, 2026

Over the trailing 12 months, BLTE insiders sold $40.39 million worth of shares (220.91K shares) in open-market trades, with no open-market purchases.

• A count shows 4 insiders selling BLTE stock on the open market over the past 12 months and none buying.
• Yu-Hsin Lin (Chief Executive Officer) led open-market sales of Belite Bio stock over the past 12 months with $20.82 million (110K shares), most recently on September 8, 2026.
• The newest open-market trade among Belite Bio insiders came on October 1, 2026, when Hendrik Peter Scholl (Chief Medical Officer) made a sale of 500 shares for $82,659.
• Business Quant data puts insider holdings in BLTE at 507.98K shares across insiders' latest Form 4 filings, down 24.97% from 677.04K shares at the end of Q2 2026.
• Belite Bio insiders hold 493.48K shares directly (97.15% of their total) and 14.5K shares (2.85%) indirectly, through entities such as trusts and partnerships.
• Per Business Quant, 4 insiders of BLTE hold shares, counting officers, directors and 10% owners who have filed a Form 4 in the past two years.
• BLTE's three largest insider shareholders, per their latest Form 4 filings, are Yu-Hsin Lin (Chief Executive Officer, 253.08K shares), Hao-Yuan Chuang (Chief Financial Officer, 231.3K shares) and Hendrik Peter Scholl (Chief Medical Officer, 14.5K shares).
• The holding of Yu-Hsin Lin makes up 49.82% of all shares held by Belite Bio insiders.
• Institutional investors owned 28.25% of BLTE shares as of Q2 2026, per their 13F filings.
• Over the past 12 months, 5 insiders reported transactions in Belite Bio stock in 34 Form 4 filings.
• Insider figures for BLTE include Form 4 filings through October 5, 2026.